NL8001100A - Cytostatisch werkende geneesmiddelen of farmaceutische preparaten. - Google Patents
Cytostatisch werkende geneesmiddelen of farmaceutische preparaten. Download PDFInfo
- Publication number
- NL8001100A NL8001100A NL8001100A NL8001100A NL8001100A NL 8001100 A NL8001100 A NL 8001100A NL 8001100 A NL8001100 A NL 8001100A NL 8001100 A NL8001100 A NL 8001100A NL 8001100 A NL8001100 A NL 8001100A
- Authority
- NL
- Netherlands
- Prior art keywords
- compounds
- days
- mice
- tgi
- isocyanurate
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title description 4
- 230000001085 cytostatic effect Effects 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 33
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- OUPZKGBUJRBPGC-IWSPIJDZSA-N 1,3,5-tris[[(2r)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@@H]1CO1 OUPZKGBUJRBPGC-IWSPIJDZSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000003211 malignant effect Effects 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- OUPZKGBUJRBPGC-UHFFFAOYSA-N 1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione Chemical class O=C1N(CC2OC2)C(=O)N(CC2OC2)C(=O)N1CC1CO1 OUPZKGBUJRBPGC-UHFFFAOYSA-N 0.000 claims 1
- ZFSLODLOARCGLH-UHFFFAOYSA-N isocyanuric acid Chemical compound OC1=NC(O)=NC(O)=N1 ZFSLODLOARCGLH-UHFFFAOYSA-N 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000002152 alkylating effect Effects 0.000 abstract description 3
- SNKDCTFPQUHAPR-UHFFFAOYSA-N 1-fluoropyrimidine-2,4-dione Chemical compound FN1C=CC(=O)NC1=O SNKDCTFPQUHAPR-UHFFFAOYSA-N 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 23
- 238000007912 intraperitoneal administration Methods 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2r)-oxiran-2-yl]methyl]-3-[[(2s)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 239000000824 cytostatic agent Substances 0.000 description 4
- 125000003055 glycidyl group Chemical group C(C1CO1)* 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003327 cancerostatic effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- ARXJGSRGQADJSQ-UHFFFAOYSA-N 1-methoxypropan-2-ol Chemical compound COCC(C)O ARXJGSRGQADJSQ-UHFFFAOYSA-N 0.000 description 2
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000004593 Epoxy Substances 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 125000005394 methallyl group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- OHXAOPZTJOUYKM-UHFFFAOYSA-N 3-Chloro-2-methylpropene Chemical compound CC(=C)CCl OHXAOPZTJOUYKM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- KOVAQMSVARJMPH-UHFFFAOYSA-N 4-methoxybutan-1-ol Chemical compound COCCCCO KOVAQMSVARJMPH-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 201000008228 Ependymoblastoma Diseases 0.000 description 1
- 206010014968 Ependymoma malignant Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 208000007093 Leukemia L1210 Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- OJYGBLRPYBAHRT-UHFFFAOYSA-N alphachloralose Chemical compound O1C(C(Cl)(Cl)Cl)OC2C(O)C(C(O)CO)OC21 OJYGBLRPYBAHRT-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000006735 epoxidation reaction Methods 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- -1 glycol ethers Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2907349 | 1979-02-24 | ||
| DE2907349A DE2907349C2 (de) | 1979-02-24 | 1979-02-24 | Arzneimittel mit cytostatischer Wirksamkeit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8001100A true NL8001100A (nl) | 1980-08-26 |
Family
ID=6063886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8001100A NL8001100A (nl) | 1979-02-24 | 1980-02-22 | Cytostatisch werkende geneesmiddelen of farmaceutische preparaten. |
Country Status (18)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT371816B (de) * | 1979-10-08 | 1983-08-10 | Henkel Kgaa | Verfahren zur herstellung von neuen isocyanurs[urederivaten |
| DE3175281D1 (en) * | 1980-01-31 | 1986-10-16 | Henkel Kgaa | Medicaments with cytostatic activity and use of cyclic compounds, in which the heterocyclic n-ring atoms are substituted by several glycidyl groups, in pharmaceutical compositions |
| AT372382B (de) * | 1980-08-14 | 1983-09-26 | Henkel Kgaa | Verfahren zur herstellung von neuen oxiranylisocyanursaeureverbindungen |
| DE3131396A1 (de) * | 1981-08-07 | 1983-03-24 | Henkel KGaA, 4000 Düsseldorf | "neue diglycidyl-pteridin-verbindungen, verfahren zu ihrer herstellung und ihre anwendung in arzneimitteln mit cytostatischer wirkung" |
| DE3131365A1 (de) * | 1981-08-07 | 1983-02-24 | Henkel KGaA, 4000 Düsseldorf | Neue diglycidyl-substituierte heterocyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung in arzneimittelzubereitungen mit cytostatischer wirksamkeit |
| DE3133077A1 (de) * | 1981-08-21 | 1983-03-10 | Henkel KGaA, 4000 Düsseldorf | Neue cytostatisch wirksame epoxidgruppen tragende 1,3,2-oxazaphosphorin-verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung in pharmazeutischen zubereitungen |
| TWI243169B (en) | 1998-03-02 | 2005-11-11 | Nissan Chemical Ind Ltd | Optically active epoxy compound |
-
1979
- 1979-02-24 DE DE2907349A patent/DE2907349C2/de not_active Expired
-
1980
- 1980-02-18 EP EP80100806A patent/EP0014981B1/de not_active Expired
- 1980-02-18 AT AT80100806T patent/ATE716T1/de not_active IP Right Cessation
- 1980-02-21 BE BE0/199482A patent/BE881834A/fr not_active IP Right Cessation
- 1980-02-22 IE IE362/80A patent/IE49274B1/en unknown
- 1980-02-22 NZ NZ192945A patent/NZ192945A/en unknown
- 1980-02-22 SE SE8001425A patent/SE8001425L/ not_active Application Discontinuation
- 1980-02-22 AU AU55830/80A patent/AU536270B2/en not_active Ceased
- 1980-02-22 LU LU82190A patent/LU82190A1/de unknown
- 1980-02-22 ZA ZA00801017A patent/ZA801017B/xx unknown
- 1980-02-22 IT IT20100/80A patent/IT1147330B/it active
- 1980-02-22 CH CH143980A patent/CH645893A5/de not_active IP Right Cessation
- 1980-02-22 IL IL59453A patent/IL59453A/xx unknown
- 1980-02-22 NL NL8001100A patent/NL8001100A/nl not_active Application Discontinuation
- 1980-02-22 FR FR8003962A patent/FR2449451A1/fr active Granted
- 1980-02-22 GB GB8006109A patent/GB2044614B/en not_active Expired
- 1980-02-23 JP JP2214580A patent/JPS55118484A/ja active Granted
- 1980-02-25 CA CA346,385A patent/CA1123740A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IT8020100A0 (it) | 1980-02-22 |
| ZA801017B (en) | 1981-02-25 |
| JPS55118484A (en) | 1980-09-11 |
| SE8001425L (sv) | 1980-08-25 |
| EP0014981B1 (de) | 1982-02-24 |
| BE881834A (fr) | 1980-08-21 |
| LU82190A1 (de) | 1980-09-24 |
| CH645893A5 (de) | 1984-10-31 |
| IL59453A (en) | 1984-02-29 |
| DE2907349A1 (de) | 1980-08-28 |
| AU536270B2 (en) | 1984-05-03 |
| FR2449451B1 (enrdf_load_stackoverflow) | 1982-12-10 |
| GB2044614A (en) | 1980-10-22 |
| GB2044614B (en) | 1983-01-26 |
| NZ192945A (en) | 1984-05-31 |
| DE2907349C2 (de) | 1982-09-16 |
| ATE716T1 (de) | 1982-03-15 |
| IE49274B1 (en) | 1985-09-04 |
| EP0014981A3 (en) | 1981-02-11 |
| IL59453A0 (en) | 1980-05-30 |
| IT1147330B (it) | 1986-11-19 |
| JPS6354688B2 (enrdf_load_stackoverflow) | 1988-10-28 |
| AU5583080A (en) | 1980-09-04 |
| EP0014981A2 (de) | 1980-09-03 |
| CA1123740A (en) | 1982-05-18 |
| FR2449451A1 (fr) | 1980-09-19 |
| IE800362L (en) | 1980-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4885171A (en) | Use of rapamycin in treatment of certain tumors | |
| Jenkins et al. | Synthesis and evaluation of. alpha.-[[(2-haloethyl) amino] methyl]-2-nitro-1H-imidazole-1-ethanols as prodrugs of. alpha.-[(1-aziridinyl) methyl]-2-nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogs which are radiosensitizers and bioreductively activated cytotoxins | |
| AU706494B2 (en) | Radiosensitizing diamines and their pharmaceutical preparations | |
| HK1045462B (zh) | 含吗啉蒽环类衍生物和抗癌剂的联合制剂 | |
| NL8001100A (nl) | Cytostatisch werkende geneesmiddelen of farmaceutische preparaten. | |
| HU226890B1 (en) | Illudin analogs useful as antitumor agents and pharmaceutical compositions containing them | |
| PL125862B1 (en) | Process for preparing novel n-substituted derivatives of diglycidylisocyanuric acid | |
| JPH07505380A (ja) | ガン治療に使用するためのメラミン誘導体 | |
| CA1226295A (en) | Glycolic acid type platinum complexes | |
| US5378456A (en) | Antitumor mitoxantrone polymeric compositions | |
| NO792398L (no) | Anvendelse av sarkosin og sarkosinderivater som tumorhemmende bestanddeler, og fremgangsmaate ved fremstillinhg av disse | |
| WO1999052888A1 (en) | Butenolide derivatives as anti-cancer agents | |
| AU2003298077A1 (en) | Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours | |
| US20230024341A1 (en) | Platinum(iv) complexes, methods of manufacture, compositions containing, and methods of use thereof | |
| HU194809B (en) | Process for producing acyl-enamide compounds and pharmaceutical compositions containing them as active components | |
| EP0390138B1 (en) | Platinum complexes and antitumor agents containing them as an active ingredient | |
| SE436208B (sv) | Sett att framstella 5-fluoro-uracilderivat | |
| EP0214862B1 (en) | Anti-tumour platinum complexes, their preparation and their use | |
| US4686215A (en) | Pharmaceutical composition and method for treating tumors susceptible to 2-carbamoylaziridine | |
| US4332934A (en) | 13-(1-Oxyl-2,2,6,6-tetramethylpiperylidenyl-4)hydrazone rubomycin hydrochloride with a paramagnetic center and a method of producing same | |
| EP0525573A1 (en) | Organogermanium and organosilicon compounds, process for the preparation of the same and use thereof | |
| JPS61249976A (ja) | グリシジルアミン含有細胞増殖抑制活性薬物 | |
| WO1982000644A1 (en) | 5,6-o-isoalkylidene ascorbic acid derivatives | |
| GB2036554A (en) | Anthraquinones for use in therapy | |
| DE2953309A1 (de) | Cytostatisch wirkende arzneimittel bzw. pharmazeutische zubereitungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BV | The patent application has lapsed |